Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes-Reference-Cited by-同舟云学术

Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes

Published:2020-04-14 Issue:14 Volume:323 Page:1353
ISSN:0098-7484
Container-title:JAMA
language:en
Short-container-title:JAMA

Author:

Petrie Mark C.¹,Verma Subodh²,Docherty Kieran F.¹,Inzucchi Silvio E.³,Anand Inder⁴,Belohlávek Jan⁵,Böhm Michael⁶,Chiang Chern-En⁷⁸,Chopra Vijay K.⁹,de Boer Rudolf A.¹⁰,Desai Akshay S.¹¹,Diez Mirta¹²,Drozdz Jaroslaw¹³,Dukát Andre¹⁴,Ge Junbo¹⁵,Howlett Jonathan¹⁶,Katova Tzvetana¹⁷,Kitakaze Masafumi¹⁸,Ljungman Charlotta E. A.¹⁹,Merkely Béla²⁰,Nicolau Jose C.²¹,O'Meara Eileen²²,Vinh Pham Nguyen²³,Schou Morten²⁴,Tereshchenko Sergey²⁵,Køber Lars²⁶,Kosiborod Mikhail N.²⁷,Langkilde Anna Maria²⁸,Martinez Felipe A.²⁹,Ponikowski Piotr³⁰,Sabatine Marc S.¹¹,Sjöstrand Mikaela²⁸,Solomon Scott D.¹¹,Johanson Per²⁸,Greasley Peter J.³¹,Boulton David³²,Bengtsson Olof²⁸,Jhund Pardeep S.¹,McMurray John J. V.¹

Affiliation:

1. British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom

2. Division of Cardiac Surgery, St Michael’s Hospital, University of Toronto, Toronto, Ontario, Canada

3. Section of Endocrinology, Yale University School of Medicine, New Haven, Connecticut

4. Department of Cardiology, University of Minnesota, Minneapolis

5. Second Department of Internal Medicine, Cardiovascular Medicine, General Teaching Hospital, First Faculty of Medicine, Charles University, Prague, Czech Republic

6. Department of Medicine, Saarland University Hospital, Homburg/Saar, Germany

7. Division of Cardiology, Taipei Veterans General Hospital, Taipei, Taiwan

8. National Yang-Ming University, Taipei, Taiwan

9. Department of Cardiology, Medanta, Gurgaon, Haryana, India

10. Department of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands

11. Cardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts

12. Division of Cardiology, Instituto Cardiovascular de Buenos Aires, Buenos Aires, Argentina

13. Department Cardiology, Medical University of Lodz, Lodz, Poland

14. Fifth Department of Internal Medicine, Comenius University in Bratislava, Bratislava, Slovakia

15. Shanghai Institute of Cardiovascular Disease, Department of Cardiology, Zhongshan Hospital Fudan University, Shanghai, China

16. Libin Cardiovascular Institute, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada

17. Clinic of Cardiology, National Cardiology Hospital, Sofia, Bulgaria

18. Cardiovascular Division of Medicine, National Cerebral and Cardiovascular Center, Osaka, Japan

19. Institute of Medicine, Department of Molecular and Clinical Medicine/Cardiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden

20. Heart and Vascular Center, Semmelweis University, Budapest, Hungary

21. Instituto do Coracao (InCor), Hospital das Clínicas Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil

22. Department of Cardiology, Montreal Heart Institute, Montreal, Ontario, Canada

23. Department of Internal Medicine, Tan Tao University, Tan Duc, Vietnam

24. Department of Cardiology, Gentofte University Hospital Copenhagen, Copenhagen, Denmark

25. Department of Myocardial Disease and Heart Failure, National Medical Research Center of Cardiology, Moscow, Russia

26. Department of Cardiology Copenhagen University Hospital, Copenhagen, Denmark

27. St Luke's Mid America Heart Institute, University of Missouri-Kansas City, Kansas City

28. Late Stage Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden

29. Universidad Nacional de Córdoba, Córdoba, Argentina

30. Center for Heart Diseases, University Hospital, Wroclaw Medical University, Wroclaw, Poland

31. Early Discovery and Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden

32. Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland

Publisher

American Medical Association (AMA)

Subject

General Medicine

Link

https://jamanetwork.com/journals/jama/articlepdf/2763950/jama_petrie_2020_oi_200021_1617397932.1056.pdf

Reference32 articles.

1. Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes.;Meng;J Med Chem,2008

2. Inhibition of SGLT2: a novel strategy for treatment of type 2 diabetes mellitus.;Pfister;Clin Pharmacol Ther,2011

3. The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure.;Thomas;Diabetologia,2018

4. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes.;Zinman;N Engl J Med,2015

5. Canagliflozin and cardiovascular and renal events in type 2 diabetes.;Neal;N Engl J Med,2017

Cited by 325 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Performance of sodium-glucose cotransporter 2 inhibitors in cardiovascular disease;Journal of Cardiovascular Medicine;2024-02-01

2. Chapter 3: Clinical Trials of Sodium-Glucose Co-Transporter-2 Inhibitors for Treatment of Heart Failure;The American Journal of Medicine;2024-02

3. The effect of sodium–glucose cotransporter 2 inhibitors on left cardiac remodelling in heart failure with reduced ejection fraction: Systematic review and meta‐analysis;European Journal of Heart Failure;2024-01-18

4. Heart Failure and Diabetes;Textbook of Diabetes;2024-01-12

5. Efficacy and safety of Abelmoschus manihot capsule combined with ACEI/ARB on diabetic kidney disease: a systematic review and meta analysis;Frontiers in Pharmacology;2024-01-05